Additionally, gatipotuzumab, a humanized monoclonal antibody recognizing TA-MUC1, was tested in a phase II study (NCT01899599) (Table 1, Fig. 3) for its efficacy and safety as a maintenance therapy in patients with TA-MUC1-positive recurrent ovarian cancer. Here, MUC1 is linked to ovarian cancer.